PPARs: therapeutic targets for metabolic disease.

By J. Berger, T. Akiyama, P. Meinke. TIPS - Trends in Pharmacological Sciences, 2005

711 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases (2011, background): “In vivo and In vitro studies demonstrate that PPAR-α plays a central role in lipid and lipoprotein metabolism, and thereby decreases dyslipidemia associated with metabolic syndrome.[13-15] In the fasting state, PPAR-α is activated by adipose-derived FAs, thereby enhancing the generation of ketone bo”
International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors (2006, background): “Because of their various metabolic and therapeutic actions, PPARs have become major drug targets (Berger et al., 2005; Staels and Fruchart, 2005).”
Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review (2014, background): “PPARg, the molecular target of the thiazolidinediones, is particularly involved in the regulation of insulin sensitivity, inflammation, fatty acid storage, and glucose metabolism, and therefore represents an especially interesting pharmacological target which is able to simultaneously modulate sever”